1132825-72-9

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 

Downstream Products

• 1132825-74-1 4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzoic acid methyl ester 
• 1132825-27-4 4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-N-{4-[4-(propane-1-sulfonyl)-piperazin-1-ylmethyl]-phenyl}-benzamide 
• 1132825-89-8 C₁₅H₁₅N₃O₂ 

Relevant academic research and scientific papers

Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity

The synthesis of two series of novel substituted pyrimidine derivatives bearing a sulfamide group have been described and their in vitro cancer growth inhibition activities have been evaluated against three human tumour cell lines (HT-29, M21, and MCF7). In general, growth inhibition activity has been enhanced by the introduction of a bulky substituent on the aromatic ring with the best compound having GI50??6?μM for all the human tumour cell lines. The MCF7 selective compounds were evaluated on four additional human invasive breast ductal carcinoma cell lines (MDA-MB-231, MDA-MB-468, SKBR3, and T47D) and were selective against T47D cell line in all cases except one, suggesting a potential antiestrogen activity.

HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C

Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or alleviating HCV, formula (I): wherein R1, R2, R4, Y1, Y2, Y3, A, B and W are as defined in the specification.